Using clinical trial data and linked administrative health data to reduce the risk of adverse events associated with the uptake of newly released drugs by older Australians: a model process

Whitstock, Margaret T.; Pearce, Christopher M.; Ridout, Stephen C.; Eckermann, Elizabeth J.
January 2011
BMC Public Health;2011, Vol. 11 Issue 1, p361
Academic Journal
Background: The study was undertaken to evaluate the contribution of a process which uses clinical trial data plus linked de-identified administrative health data to forecast potential risk of adverse events associated with the use of newly released drugs by older Australian patients. Methods: The study uses publicly available data from the clinical trials of a newly released drug to ascertain which patient age groups, gender, comorbidities and co-medications were excluded in the trials. It then uses linked deidentified hospital morbidity and medications dispensing data to investigate the comorbidities and co-medications of patients who suffer from the target morbidity of the new drug and who are the likely target population for the drug. The clinical trial information and the linked morbidity and medication data are compared to assess which patient groups could potentially be at risk of an adverse event associated with use of the new drug. Results: Applying the model in a retrospective real-world scenario identified that the majority of the sample group of Australian patients aged 65 years and over with the target morbidity of the newly released COX-2-selective NSAID rofecoxib also suffered from a major morbidity excluded in the trials of that drug, indicating a substantial potential risk of adverse events amongst those patients. This risk was borne out in post-release morbidity and mortality associated with use of that drug. Conclusions: Clinical trial data and linked administrative health data can together support a prospective assessment of patient groups who could be at risk of an adverse event if they are prescribed a newly released drug in the context of their age, gender, comorbidities and/or co-medications. Communication of this independent risk information to prescribers has the potential to reduce adverse events in the period after the release of the new drug, which is when the risk is greatest. Note: The terms 'adverse drug reaction' and 'adverse drug event' have come to be used interchangeably in the current literature. For consistency, the authors have chosen to use the wider term 'adverse drug event' (ADE).


Related Articles

  • Westminster diary. Dalyell, Tam // New Scientist;5/7/2005, Vol. 186 Issue 2498, p47 

    The article presents the author's views on drug side effects. He says when it comes to detecting side effects, most trials are too small to find anything less than decimation. He says he would be pushing up the daisies were it not for pharmaceutical advances in the past 10 years, and owes his...

  • Impact of pneumococcal polysaccharide vaccine in people aged 65 years or older. Collignon, Peter J. // Medical Journal of Australia;8/18/2014, Vol. 201 Issue 4, p199 

    A letter to the editor is presented regarding the impact of pneumococcal polysaccharide vaccine in people with age 65 years and above.

  • Club Drugs K.O. the Young. Wetzstein, Cheryl // Insight on the News;01/10/2000, Vol. 16 Issue 2, p29 

    Discourages the use of a recreational drugs ingested to enhance experience in dance clubs called club drugs. Warning on the hazardous effects of the club drugs; Lists of club drugs; Death resulting from club drugs.

  • Post-marketing surveillance. Sullman, Susan // Journal of the Royal Society of Medicine;Jan1979, Vol. 72 Issue 1, p65 

    The article reports on the plan of the government to organize a national scheme for the regulation the pharmaceutical industry in Great Britain. The initiative was aimed to detect adverse reactions to novel bioactive compounds which have been granted a product licence and which can be freely...

  • Pharmacokinetics of drugs in the elderly. Woodhouse, K. W. // Journal of the Royal Society of Medicine (Supplement);Jul1994, Vol. 87 Issue 23, p2 

    The article discusses the pharmacokinetics of drugs in older people. Several factors contribute to the risk of developing adverse drug reactions (ADR) among elderly patients, including an alteration in pharmacokinetics, or the fate of a drug in the body. Age does not seem to be a major influence...

  • Pharmacodynamics in the elderly. Hugh, Stephen; Jackson, David // Journal of the Royal Society of Medicine (Supplement);Jul1994, Vol. 87 Issue 23, p5 

    The article examines pharmacodynamics in older people. Pharmacodynamics is defined as the study of changes in the effects of drugs with time as opposed to concentration. It involves sensitivity, or the measurement of a response to a given concentration of a drug. Mechanisms of pharmacodynamic...

  • Preventing drug reactions in the elderly: can we do better? Tallis, R. C. // Journal of the Royal Society of Medicine (Supplement);Jul1994, Vol. 87 Issue 23, p14 

    The article examines ways of preventing adverse drug reactions (ADR) in older people. Several factors lead to the incidence of ADR, including changes in the absorption, distribution, metabolism and excretion of drugs. Studies have shown the prevalence of inappropriate prescribing. A problem...

  • Drug management of arthritis in the elderly. Fleming, Anthony // Journal of the Royal Society of Medicine (Supplement);Jul1994, Vol. 87 Issue 23, p22 

    The article discusses issues related to prescribing antirheumatic drugs to older patients. Assessing the potential for toxicity and drug interactions is important when planning treatment since older people are more susceptible to the side effects of antirheumatic agents. Age affects the...

  • Antidepressants: What You Need to Know: These mood-boosting medications can be of benefit alongside psychotherapy if you suffer from depression.  // Focus on Healthy Aging;Aug2019, Vol. 22 Issue 8, p4 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics